Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Gain Therapeutics, Inc. GANX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.00
+376.2%

Gain Therapeutics, Inc. (GANX) is a Biotechnology company in the Healthcare sector, currently trading at $1.89. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is GANX = $9 (+376.2% upside).

Valuation: GANX trades at a trailing Price-to-Earnings (P/E) of -3 (S&P 500 average ~25).

Net income is $20M (loss), growing at -5.7%/yr. Net profit margin is 0% (thin). Gross margin is -45.7% (-99.9 pp trend).

Balance sheet: total debt is $732,067 against $19M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 6.63 (strong liquidity). Debt-to-assets is 3.2%. Total assets: $23M.

Analyst outlook: 7 / 8 analysts rate GANX as buy (88%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$9.00
▲ 376.19% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Gain Therapeutics, Inc., the average price target is $9.00, with a high forecast of $10.00, and a low forecast of $8.00.
Highest Price Target
$10.00
Average Price Target
$9.00
Lowest Price Target
$8.00

GANX SharesGrow Score Overview

77/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GANX

✓
VALUE Pass
100/100
GANX trades at a trailing Price-to-Earnings (P/E) of -3 (S&P 500 average ~25). Forward PEG -0.61 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $9, implying +376.2% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
GANX: -80.3%/yr revenue is, -5.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet GANX: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 6.63 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
94/100
Analyst outlook: 7 / 8 analysts rate GANX as buy (88%). Analyst consensus target is $9 (+376.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.41-4.34
Volume633.26K
Avg Volume (30D)753.29K
Market Cap$79.84M
Beta (1Y)0.11
Share Statistics
EPS (TTM)-0.61
Shares Outstanding$32.97M
IPO Date2021-03-19
Employees23
CEOKhalid Islam
Financial Highlights & Ratios
Gross Profit$-94.05K
EBITDA$-18.62M
Net Income$-20.16M
Operating Income$-18.71M
Total Cash$20.84M
Total Debt$732.07K
Net Debt$-20.11M
Total Assets$22.82M
Price / Earnings (P/E)-3.1
Analyst Forecast
1Y Price Target$9.00
Target High$10.00
Target Low$8.00
Upside+376.2%
Rating ConsensusBuy
Analysts Covering8
Buy 88% Hold 13% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS36269B1052

Price Chart

Track all markets on TradingView
GANX
Gain Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.41 52WK RANGE 4.34

People Also View

CELC
CELC
Celcuity Inc.
$120.85
+0.37%
 NAMS
NAMS
NewAmsterdam Pharma Company N.V.
$34.44
-4.99%
 ELVN
ELVN
Enliven Therapeutics, Inc.
$44.85
+2.33%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.19
+7.40%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.69
+2.23%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 MACK
MACK
Merrimack Pharmaceuticals, Inc.
$15.15
+0.10%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message